Omaveloxolone for the Treatment of Friedreich’s Ataxia-Reference-Cited by-同舟云学术

Omaveloxolone for the Treatment of Friedreich’s Ataxia

Published:2023 Issue:2 Volume:19 Page:2
ISSN:1758-4000
Container-title:US Neurology
language:en
Short-container-title:

Author:

Kessler Riley,Sharma Sonal,Lynch David R, , , , ,

Abstract

Friedrich’s ataxia (FRDA), a neurodevelopmental and progressive neurodegenerative disease, is the most common inherited form of ataxia. Omaveloxolone was approved by the US Food and Drugs Administration in early 2023, making it the first treatment available to patients with FRDA. This approval was made possible by combining a compelling cellular mechanism and strong clinical evidence provided through the MOXIe study, the multipart clinical trial evaluating the efficacy of omaveloxolone in patients with FRDA. This review discusses the underlying cellular pathology and proposed mechanism of omaveloxolone in FRDA. The MOXIe study is presented in detail, including a discussion of the challenges faced in clinical trials in FRDA, and rare diseases more broadly. Finally, other therapies under investigation are reviewed briefly.

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Subject

Neurology (clinical),General Neuroscience

Reference66 articles.

1. Cossée M, Schmitt M, Campuzano V, et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: Founder effect and premutations. Proc Natl Acad Sci U S A. 1997;94:7452–7. DOI: 10.1073/pnas.94.14.7452.

2. Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89:212–25. DOI: 10.1002/ana.25934.

3. Campuzano V, Montermini L, Moltò MD, et al. Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–7. DOI: 10.1126/science.271.5254.1423.

4. Galea CA, Huq A, Lockhart PJ, et al. Compound heterozygous FXN mutations and clinical outcome in Friedreich ataxia. Ann Neurol. 2016;79:485–95. DOI: 10.1002/ana.24595.

5. Koutnikova H, Campuzano V, Koenig M. Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum Mol Genet. 1998;7:1485–9. DOI: 10.1093/hmg/7.9.1485.